13D Filing: Biotechnology Value Fund LP and CTI Biopharma Corp (CTIC)

SCHEDULE A

Transactions in the Securities
of the Issuer During the Past Sixty Days

Class of Security

Securities Purchased / (Sold)

Price ($)

Date of Purchase / Sale

 

BIOTECHNOLOGY VALUE FUND, L.P.

Series N3 Preferred Stock*	3,292*	2,000.00	06/09/2017
Common Stock	2,007,333	*	06/09/2017

 

BIOTECHNOLOGY VALUE FUND II, L.P.

Series N3 Preferred Stock*	2,312*	2,000.00	06/09/2017
Common Stock	1,410,000	*	06/09/2017

BIOTECHNOLOGY VALUE TRADING FUND
OS LP

Series N3 Preferred Stock*	561*	2,000.00	06/09/2017
Common Stock	342,000	*	06/09/2017

BVF PARTNERS L.P. (THROUGH THE
PARTNERS MANAGEMENT ACCOUNTS)

Series N3 Preferred Stock*	585*	2,000.00	06/09/2017
Common Stock	357,333	*	06/09/2017

* In connection with the letter agreement, as further described
in Item 6, on June 9, 2017, 6,175 Shares of Series N3 Preferred Stock were converted into 4,116,666 Shares of Common Stock. As
a result, the Reporting Persons now only hold an aggregate of 575 Shares of Series N3 Preferred Stock.